Supplementary Appendix
|
|
- Kenneth Norton
- 6 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Zauber AG, Winawer SJ, O Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:
2 SUPPLEMENT Microsimulation Modeling Estimate of the Impact of Colonoscopic Polypectomy on Colorectal Cancer Mortality in the National Polyp Study Online Appendix: Table of Contents Summary Page 1 Introduction Page 1 Methods Page 2 Supplement Figure 1. Graphical representation of natural history of disease as modeled by MISCAN-Colon model. Page 3 Results Page 5 Discussion Page 5 References Page 8 Supplement Table 1. Characteristics of all adenoma patients at initial polypectomy as observed in the National Polyp Study and as simulated in the MISCAN-Colon model (n=2602). Supplement Table 2. Deaths from Colorectal Cancer in the Observed Adenoma Cohort with Polypectomy Compared to Simulated Adenoma Cohort without Polypectomy. Supplement Appendix Table 1. Main assumptions in the MISCAN-Colon model in simulating the National Polyp Study adenoma cohort. Page 12 Page 13 Page 14 Participating Centers in the National Polyp Study. Page 16
3 Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths (Zauber et al, N Engl J Med 2012) SUPPLEMENT: Microsimulation Modeling Estimate of the Impact of Colonoscopic Polypectomy on Mortality from Colorectal Cancer in the National Polyp Study SUMMARY In the National Polyp Study we compared the observed deaths from colorectal cancer in the adenoma cohort in which all detectable adenomas had been removed with that of a comparable simulated adenoma cohort but without polypectomy. There were 12 observed deaths from colorectal cancer in the adenoma cohort compared to 145 expected deaths from the disease based on the simulated rates for the adenoma cohort without polypectomy (MISCAN-Colon); the standardized mortality ratio was 0.08 (95% confidence interval [CI], 0.04 to 0.14). This represents a 92% reduction in mortality from colorectal cancer in the adenoma cohort with polypectomy compared with a hypothetical cohort of patients with adenomas detected but never removed. INTRODUCTION In the paper 1 we assessed the long-term impact of colonoscopic polypectomy and subsequent surveillance on mortality from colorectal cancer in newly diagnosed adenoma patients in the National Polyp Study (NPS) and demonstrated a large impact of colonoscopic polypectomy. We did so by comparing the mortality from colorectal cancer in the NPS adenoma cohort with an age, sex, race, and calendar year adjusted estimate from the general population 1
4 SEER9 rates and with a concurrent control group of patients with non-adenomatous polyps. 1 However, as discussed in the paper, a more meaningful comparison group for the NPS adenoma cohort with polypectomy would be a clinical comparison of an adenoma cohort without polypectomy. This is not an ethical or clinical option because of the known potential for adenoma progression to carcinoma. Instead, in this supplement, we addressed this comparison using a microsimulation model of mortality from colorectal cancer for a cohort of patients with adenomas in which the adenomas were ascertained but not removed and the natural history of the adenoma-carcinoma sequence proceeded without intervention. METHODS The deaths from colorectal cancer of the NPS patients with adenomas were compared to the expected deaths from colorectal cancer from a simulated adenoma cohort without polypectomy. We determined the expected number of deaths from colorectal cancer for a cohort of patients with adenomas by using a validated microsimulation model (MISCAN-Colon) to predict the natural history of individuals with adenomas with the same age and baseline disease characteristics as the NPS adenoma cohort, but without any polypectomy. 2 REFERENCE GROUP OF MICROSIMULATION MODEL OF ADENOMA COHORT WITHOUT POLYPECTOMY MISCAN-Colon Microsimulation Model The Department of Public Health at Erasmus MC, the Netherlands, developed the MISCAN-Colon microsimulation model in collaboration with the National Cancer Institute to assess the effect of different interventions on colorectal cancer. The model structure and inputs and the data sources that informed the development of the model can be found in Supplement 2
5 Appendix Table 1, in previous publications, 3-5 and also in a standardized model profile. 6 MISCAN-Colon is one of the models in the Cancer Incidence and Surveillance Modeling Network (CISNET) of the United States National Cancer Institute ( A graphic representation of the natural history in the model is given in Supplement Figure 1. Screening Adenoma States Preclinical Cancer States Clinical Cancer States no lesion adenoma 5 mm adenoma 6-9 mm adenoma 10 mm preclinical stage I preclinical stage II preclinical stage III preclinical stage IV clinical stage I clinical stage II clinical stage III clinical stage IV death colorectal cancer Supplement Figure 1. Graphical representation of natural history of disease as modeled by MISCAN-Colon model. The opportunity to intervene in the natural history through screening is noted. In brief, the MISCAN-Colon model simulates the relevant lifetimes of a large population of individuals from birth to death, first without screening and subsequently with the changes that would occur under the implementation of a screening and surveillance program. Colorectal cancer arises in this population according to the adenoma-carcinoma sequence. 7,8 More than one adenoma can occur in an individual and each can independently develop into colorectal cancer. Adenomas progress in size from small (1-5 mm) to medium (6-9 mm) to large (10+ mm). Most adenomas will never grow into cancer (non-progressive adenomas). These adenomas either stay 3
6 6-9 mm in size or continue to grow to 10 mm or larger. Some adenomas (progressive adenomas) may eventually become malignant, transforming to a stage I cancer. The cancer may then progress from stage I to stage IV. In every stage there is a probability of the cancer being diagnosed because of symptoms versus alternatively progressing without symptoms into the next stage. Meanwhile, a person may die of other causes at any time, precluding developing or dying from colorectal cancer. The survival after clinical diagnosis depends on the stage in which the cancer was detected. MISCAN-Colon simulation of the National Polyp Study cohort We used the MISCAN-Colon microsimulation model to simulate a population of adenoma patients of the same age, sex and baseline adenoma characteristics as the NPS 2 (Supplement Table 1). The participants in the NPS were subjects who had been referred for initial colonoscopy and had adenomatous polyps diagnosed and removed. The MISCAN-Colon model was adapted to this situation by applying a fictitious screening test to the general population to select individuals with positive test results who were referred to colonoscopy evaluation and had adenomas detected at diagnostic colonoscopy but the adenomas were not removed. The fictitious screening test can be regarded as a mixture of fecal occult blood test (FOBT) or sigmoidoscopy. 2 These individuals with positive screening tests constituted the simulated trial population referred for colonoscopy (Figure 1 1 ). As in the NPS, simulated individuals with a history of colorectal cancer or colorectal cancer detected at the baseline diagnostic colonoscopy were excluded from the trial population. The sensitivity and age distribution of the fictitious screening test was adjusted to reproduce the age distribution, the distribution of adenomas over the distal and proximal colon, and the size and multiplicitydistribution of adenomas at initial polypectomy in the NPS. 2 4
7 Secular trends in treatment. The NPS adenoma cohort was followed over calendar years We adjusted the natural history model without polypectomy intervention for the changes in relative survival due to improvements in treatment over this time period. The MISCAN-Colon model had simulated the United States population from 1975 to 2000 with respect to mortality from colorectal cancer as a function of changes in risk factor behavior, screening adherence, and treatment. 9 We estimated that 3% of the change in mortality from colorectal cancer in that time period was due to changes in treatment; 9 therefore we reduced the MISCAN-Colon natural history model estimates of deaths from colorectal cancer by 3% to adjust for these secular trends over time. RESULTS There were 12 observed deaths from colorectal cancer in the NPS adenoma cohort compared to 145 expected deaths from the disease based on the simulated adenoma cohort rates without polypectomy (MISCAN-Colon); the standardized mortality ratio was 0.08 (95% confidence interval [CI], 0.04 to 0.14). (Supplement Table 2). This represents a 92% reduction in CRC mortality in the adenoma cohort compared with a hypothetical cohort of patients with adenomas detected but never removed, so that the progression of adenomas to colorectal cancer and to death from colorectal cancer was not impeded by intervention. There was a comparable size reduction for the first 10 years following initial polypectomy as well as for the 10 or more years after polypectomy (Supplement Table 2). DISCUSSION Comparison of the observed deaths from colorectal cancer in the NPS adenoma cohort with colonoscopic polypectomy to that expected in a simulated hypothetical cohort without 5
8 removal of their adenomas suggests that a very large reduction in mortality from colorectal cancer (92%) could be achieved by intervening in the adenoma-carcinoma sequence with removal of adenomas. These results supplement the results presented with comparisons to a non-adenoma internal control group and the general population SEER rates to suggest that colonoscopic polypectomy in conjunction with surveillance provides a marked decrease in mortality from colorectal cancer. 1 The MISCAN-Colon model has been validated and shown high concordance with outcomes of observed clinical trials. The validity of the model is based on observational data before the introduction of screening, such as clinical incidence and mortality from colorectal cancer 10 and the size and multiplicity distribution of adenomas in autopsy and colonoscopy studies. The external validity has further been tested on the results of the National Polyp Study, 2 and other large (randomized) screening and surveillance studies, such as the CoCap sigmoidoscopy study, 3 and the Minnesota Colon Cancer Control Study. 3 In addition, the model was able to explain observed incidence and mortality trends in the United States when accounting for risk factor behaviors, screening practice and chemotherapy treatment. 9 One of the most important assumptions in the modeling is the distribution of the dwell time of the adenomas and that of preclinical cancers. This is generally an unobservable parameter but one which affects the projections of the model, especially with respect to appropriate surveillance times following initial adenoma detection. In general the MISCAN-Colon model has a shorter dwell time than other microsimulation models for colorectal cancer. 11 6
9 In conclusion, the microsimulation modeling approach suggests that colonoscopic polypectomy in an adenoma population should provide a significant reduction (92%) in mortality from colorectal cancer compared to no polypectomy. 7
10 REFERENCES 1. Zauber A, Winawer S, O'Brien M, et al. Colonoscopic polypectomy and long-term prevention of colorectal cancer deaths. N Engl J Med 2012; 366, February 23, Loeve F, Boer R, Zauber AG, et al. National Polyp Study data: evidence for regression of adenomas. International journal of cancer 2004;111: Loeve F, Boer R, Ballegooijen Mv, Oortmarssen GJv, Habbema JDF. Final Report MISCAN-COLON Microsimulation Model for Colorectal Cancer. Rotterdam: Department of Public Health, Erasmus University; Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JDF. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999;32: Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis. Journal of the National Cancer Institute 2000;92: Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Oortmarssen GJv, Loeve F. Department of Public Health. Erasmus MC. Model Profiler of the MISCAN-Colon microsimulation model for colorectal cancer. In; (accessed October 12, 2011). 7. Morson B. The polyp-cancer sequence in the large bowel. Proc R Soc Med 1974;67: Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:
11 9. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, , featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116: Surveillance Epidemiology, and End Results (SEER) Program ( SEER* Stat Database: Incidence - SEER 9 Regs Public-Use, Nov2010 Sub ( ) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission. In; Kuntz K, Lansdorp-Vogelaar I, Rutter C, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Journal of Medical Decision Making 2011;31: Arminski TC, McLean DW. Incidence and distribution of adenomatous polyps of the colon and rectum based on autopsy examinations.. Dis Colon Rectum 1964;7: Blatt LJ. Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum 1961;4: Bombi JA. Polyps of the colon in Barcelona, Spain. Cancer 1988;61: Chapman I. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg 1963;157: Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. International journal of cancer 1985;36: Jass JR, Young PJ, Robinson EM. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut 1992;33:
12 18. Johannsen LG, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol 1989;24: Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel. Cancer 1979;43: Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982;49: Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982;23: Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. American journal of epidemiology 1983;118: Gyrd-Hansen D, Sogaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997;26: Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. International journal of cancer 1997;73: Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet 1989;1: Kronborg O, Fenger C, Olsen J, Bech K, Sondergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989;24: Hixson, L. J., M. B. Fennerty, et al. (1990). Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 1990;82:
13 28. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112: Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993;328:
14 Supplement Table 1. Characteristics of All Adenoma Patients at Initial Polypectomy as Observed in the National Polyp Study and as Simulated in the MISCAN-Colon Model Characteristic Age NPS Observed Adenoma Cohort (N=2602) MISCAN Model <50 13% 11% % 27% % 40% >70 25% 23% Adenoma Size 10mm 43% 44% 10mm 57% 56% No. of adenomas 1 59% 61% 2 22% 23% 3 19% 16% 12
15 Supplement Table 2. Deaths from Colorectal Cancer in the Observed Adenoma Cohort with Polypectomy Compared to Simulated Adenoma Cohort without Polypectomy. Adenoma No. Person- NPS Microsimulation Reference Group Cohort Years at Risk MISCAN-Colon Model of Adenoma Subjects with No Polypectomy Observed Expected SMR 95%CI % Reduction P-value CRC Deaths CRC Deaths Without Polypectomy All years , % <0.001 followed < 10 years , % < years , % <
16 SUPPLEMENT APPENDIX Supplement Appendix Table 1. Main Assumptions in the MISCAN-Colon Model in Simulating the National Polyp Study Adenoma Cohort Parameter Value Based on Adenoma incidence in general population Age and sex dependent: Adenoma prevalence in autopsy and colonoscopy studies of 15% in age group to 33% in age group and cancer incidence in SEER registry in Distribution of risk for adenomas over the general population Gamma distributed, mean 1, variance 2 Multiplicity distribution of adenomas in autopsy studies Duration distributions in preclinical stages Exponential Expert opinion, other cancer models Mean duration of non-progressive adenomas Lifelong Expert opinion Mean duration of progressive adenomas 16.4 yrs Expert opinion and references 7-8 Mean duration of preclinical cancer 3.6 yrs Cancer detection rate at first screening and background cancer incidence in FOBT trials 25,26 Probability to develop cancer from 0% Expert opinion removed adenoma 14
17 Parameter Value Based on Sensitivity of initial and surveillance colonoscopic examination adenoma 5mm: 75% adenoma 6-9mm: 85% Back-to-back colonoscopy studies 27,28 adenoma 10+mm: 95% cancer: 95% Sensitivity of fictitious screening test adenoma 5mm: 15% adenoma 6-9mm: 28% adenoma 10+mm: 99% cancer: 100% Adenoma size at initial polypectomy of all patients included in the National Polyp Study The NPS cohort was constructed to represent patients referred to colonoscopy on the basis of a positive screening test comparable to that of fecal occult blood test or flexible sigmoidoscopy which were the predominant screening reasons for referral to the NPS. Reach of initial and surveillance 100% National Polyp Study design 29 colonoscopic examination 15
18 PARTICIPATING CENTERS IN THE NATIONAL POLYP STUDY The seven centers participating in the National Polyp study are the Memorial Sloan- Kettering Cancer Center (New York, NY), SJ Winawer (PI); Mt. Sinai Medical Center (New York, NY) JD Waye (PI); Veterans Affairs Medical Center (Minneapolis, MN), JH Bond (PI); Medical College of Wisconsin (Milwaukee, WI), E Stewart and W Hogan (PI s); Massachusetts General Hospital (Boston, MA), S. Hedberg (deceased), F. Ackroyd (PIs) ; Cedars-Sinai Medical Center (Los Angeles, CA), J Panish (PI); and Valley Presbyterian Hospital (Van Nuys, CA), M. Schapiro (PI). The Mallory Institute of Pathology, Boston University School of Medicine (Boston, MA) was the site for pathology review team: MJ O Brien (Boston University), SS Sternberg (Memorial Sloan-Kettering), and LS Gottlieb (Boston University) (deceased). 16
Supplementary Online Content
Supplementary Online Content Meester R.G.S, Doubeni CA, Lansdorp-Vogelaar, et al. Variation in adenoma detection rate and the lifetime benefits and cost of colorectal cancer screening: a microsimulation
More informationAppendix 1 This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix 1 This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Cenin DR, St John DJB, Ledger MJN, et al. Optimising the
More informationC olorectal adenomas are reputed to be precancerous
568 COLORECTAL CANCER Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese Y Yamaji, T Mitsushima, H Ikuma, H Watabe, M Okamoto, T
More informationA BS TR AC T. n engl j med 366;8 nejm.org february 23,
The new england journal of medicine established in 1812 february 23, 2012 vol. 366 no. 8 Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths Ann G. Zauber, Ph.D., Sidney J. Winawer,
More informationCitation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy
UvA-DARE (Digital Academic Repository) Population screening for colorectal cancer by colonoscopy de Wijkerslooth, T.R. Link to publication Citation for published version (APA): Wijkerslooth de Weerdesteyn,
More informationStool DNA Testing to Screen for Colorectal Cancer in the Medicare Population A Cost-Effectiveness Analysis
Article Annals of Internal Medicine Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population A Cost-Effectiveness Analysis Iris Lansdorp-Vogelaar, PhD; Karen M. Kuntz, ScD; Amy B. Knudsen,
More informationEstimation of screening test (Hemoccult ) sensitivity in colorectal cancer mass screening
doi: 1.154/ bjoc.21.1752, available online at http://www.idealibrary.com on http://www.bjcancer.com Estimation of screening test (Hemoccult ) sensitivity in colorectal cancer mass screening JL Jouve 1,
More informationColorectal cancer is the second leading cause of cancer-related. Colonoscopic Miss Rates for Right-Sided Colon Cancer: A Population-Based Analysis
GASTROENTEROLOGY 2004;127:452 456 Colonoscopic Miss Rates for Right-Sided Colon Cancer: A Population-Based Analysis BRIAN BRESSLER,* LAWRENCE F. PASZAT,, CHRISTOPHER VINDEN,, CINDY LI, JINGSONG HE, and
More informationCRC screening at age 45 What does the modeling suggest?
CRC screening at age 45 What does the modeling suggest? Elisabeth Peterse Erasmus University Medical Center, Rotterdam, The Netherlands Possible conflicts of interest No disclosures. Elisabeth Peterse
More informationThe MISCAN-COLON simulation model for the evaluation of colorectal cancer screening
2 The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening 30 Chapter 2 Abstract A general model for evaluation of colorectal cancer screening has been implemented in the microsimulation
More informationFecal Occult Blood Testing When Colonoscopy Capacity is Limited
DOI: 10.1093/jnci/djr385 Advance Access publication on November 9, 2011. The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationThe Canadian Cancer Society estimates that in
How Do I Screen For Colorectal Cancer? By Ted M. Ross, MD, FRCS(C); and Naomi Ross, RD, BSc To be presented at the University of Toronto s Primary Care Today sessions (October 3, 2003) The Canadian Cancer
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2000, by the Massachusetts Medical Society VOLUME 342 J UNE 15, 2000 NUMBER 24 A COMPARISON OF COLONOSCOPY AND DOUBLE-CONTRAST FOR SURVEILLANCE AFTER POLYPECTOMY
More informationCost-effectiveness of adenoma surveillance - the Dutch guidelines -
Cost-effectiveness of adenoma surveillance - the Dutch guidelines - WEO working group adenoma surveillance 20 May, 2016 Iris Lansdorp-Vogelaar, PhD On behalf of the SAP study-group Introduction Adenoma
More informationScreening for colorectal cancer (CRC) has proven effectiveness. Colorectal Cancers Detected After Colonoscopy Frequently Result From Missed Lesions
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:858 864 Colorectal Cancers Detected After Colonoscopy Frequently Result From Missed Lesions HEIKO POHL*,,, and DOUGLAS J. ROBERTSON*,, *Outcomes Group and
More informationColorectal Cancer Screening What are my options?
069-Colorectal cancer (Rosen) 1/23/04 12:59 PM Page 69 What are my options? Wayne Rosen, MD, FRCSC As presented at the 37th Annual Mackid Symposium: Cancer Care in the Community (May 22, 2003) There are
More informationDo Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis
Research Article Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis Miriam P. van der Meulen 1, Atija Kapidzic 2, Monique E. van Leerdam 3,
More informationEffects and costs of colorectal cancer screening and follow-up after polypectomy
Effects and costs of colorectal cancer screening and follow-up after polypectomy Franka Loeve This thesis is partly realized due to the financial support of the Department of Public Health, Erasmus MC,
More informationComputed tomographic colonography (CTC), popularly referred
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:237 244 The Management of Small Polyps Found by Virtual Colonoscopy: Results of a Decision Analysis CHIN HUR,*,, DANIEL C. CHUNG,*, ROBERT E. SCHOEN, and
More informationEstimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies Modeling Study for the US Preventive Services Task Force
Clinical Review & Education US Preventive Services Task Force MODELING STUDY Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies Modeling Study for the US Preventive Services
More informationSection I Early Colorectal Cancer
Section I Early Colorectal Cancer CHAPTER 1 SETTING THE SCENE 1.1 Colorectal Cancer in Australia Colorectal Cancer is unequivocally a major health problem in Australia. It is the most common cancer reported
More informationCost-effectiveness Model for Colon Cancer Screening
GASTROENTEROLOGY 1995;109:1781-1790 Cost-effectiveness Model for Colon Cancer Screening DAVID A. LIEBERMAN Division of Gastroenterology, Department of Medicine, Oregon Health Sciences University, and Portland
More informationR. J. L. F. Loffeld, 1 P. E. P. Dekkers, 2 and M. Flens Introduction
ISRN Gastroenterology Volume 213, Article ID 87138, 5 pages http://dx.doi.org/1.1155/213/87138 Research Article The Incidence of Colorectal Cancer Is Decreasing in the Older Age Cohorts in the Zaanstreek
More informationThe American College of Radiology Imaging Network enrolled 2600 asymptomatic subjects aged 50 years or older into the American College of Radiology Im
Note: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Comparative Economic
More informationC olorectal cancer (CRC) is the second most common
CANCER Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial J H Scholefield, S Moss, F Sufi, C M Mangham, J D Hardcastle... See end of
More informationRandomised study of screening for colorectal cancer with faecaloccult-blood
Articles Randomised study of screening for colorectal cancer with faecaloccult-blood test Ole Kronborg, Claus Fenger, Jørn Olsen, Ole Dan Jørgensen, Ole Søndergaard Summary Background Case-control studies
More informationColorectal Cancer Screening Differential Costs for Younger Versus Older Americans
Colorectal Cancer Screening Differential Costs for Younger Versus Older Americans Uri Ladabaum, MD, MS, Kathryn A. Phillips, PhD Background: Methods: Results: Conclusions: Colorectal cancer (CRC) incidence
More informationColorectal Cancer Screening and Surveillance
1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1258 ISSN 1175 8716 A survey of colonoscopy capacity in New Zealand s public hospitals Andrew Yeoman, Susan Parry Abstract Aims Population screening for colorectal
More informationCost effectiveness of colorectal cancer screening in Ukraine
https://doi.org/10.1186/s12962-018-0104-0 Cost Effectiveness and Resource Allocation RESEARCH Open Access Cost effectiveness of colorectal cancer screening in Ukraine Nelya Melnitchouk 1*, Djøra I. Soeteman
More informationIncreasing the number of older persons in the United
Current Capacity for Endoscopic Colorectal Cancer Screening in the United States: Data from the National Cancer Institute Survey of Colorectal Cancer Screening Practices Martin L. Brown, PhD, Carrie N.
More informationArrospide et al. BMC Cancer (2018) 18:464
Arrospide et al. BMC Cancer (2018) 18:464 https://doi.org/10.1186/s12885-018-4362-1 RESEARCH ARTICLE Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Colon Polyp Recurrence in a Managed Care Population Marianne Ulcickas Yood, DSc, MPH; Susan Oliveria, ScD, MPH; J. Gregory Boyer, PhD; Karen Wells, BS; Paul Stang, PhD; Christine
More informationThe effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial
Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an
More informationE Thiis-Evensen, G S HoV, J Sauar, B M Majak, M H Vatn
834 Department of Medicine, Telemark Central Hospital, Skien, Norway E Thiis-Evensen GSHoV J Sauar Department of Pathology, Telemark Central Hospital, Skien, Norway B M Majak Department A of Medicine,
More informationNatural History of Colorectal Adenomas: Birth Cohort Analysis Among 3.6 Million Participants of Screening Colonoscopy
Research Article Cancer Epidemiology, Biomarkers & Prevention Natural History of Colorectal Adenomas: Birth Cohort Analysis Among 3.6 Million Participants of Screening Colonoscopy Hermann Brenner 1, Lutz
More informationCURRENT GUIDELINES FOR
ORIGINAL CONTRIBUTION Screening Colonoscopy in Very Elderly Patients Prevalence of Neoplasia and Estimated Impact on Life Expectancy Otto S. Lin, MD, MSc Richard A. Kozarek, MD Drew B. Schembre, MD Kamran
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationFecal occult blood tests: a cost-effectiveness analysis Gyrd-Hansen D
Fecal occult blood tests: a cost-effectiveness analysis Gyrd-Hansen D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract
More informationThe New England Journal of Medicine. IMPORTANCE OF ADENOMAS 5 mm OR LESS IN DIAMETER THAT ARE DETECTED BY SIGMOIDOSCOPY
IMPORTANCE OF ADENOMAS mm OR LESS THAT ARE DETECTED BY SIGMOIDOSCOPY THOMAS E. READ, M.D., JULIE D. READ, R.N., AND LYNN F. BUTTERLY, M.D. ABSTRACT Background The need for colonoscopy in patients with
More informationScreening for Colorectal Cancer in the Elderly. The Broad Perspective
Screening for Colorectal Cancer in the Elderly Charles J. Kahi, MD, MSCR Indiana University School of Medicine Richard L. Roudebush VA Medical Center Indianapolis, Indiana ACG Regional Midwest Course Symposium
More informationTitle Description Type / Priority
Merit-based Incentive Payment system (MIPS) 2019 Qualified Clinical Data Registry (QCDR) Measure Specifications Summary Listing of QCDR measures supported by the NHCR Measure # NHCR4 NHCR5 GIQIC12 GIQIC15
More informationSCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE
SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal
More informationColorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital
Colorectal Cancer Screening Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital March, 2018 CRC Epidemiology 4th most common malignancy in US (136,000 cases/yr) 2nd
More informationThe Dutch bowel cancer screening program Relevant lessions for Ontario
The Dutch bowel cancer screening program Relevant lessions for Ontario Ernst J Kuipers Erasmus MC University Medical Center Rotterdam - The Netherlands 1 Ismar Boas (1858 1938) Colorectal cancer screening
More informationEarly release, published at on July 12, Subject to revision. The cost-effectiveness of screening for colorectal cancer
Early release, published at www.cmaj.ca on July 12, 2010. Subject to revision. Research The cost-effectiveness of screening for colorectal cancer Jennifer J. Telford MD FRCPC, Adrian R. Levy PhD, Jennifer
More informationOptimising the expansion of the National Bowel Cancer Screening Program. Abstract. Methods. MISCAN-Colon model
Optimising the expansion of the National Bowel Cancer Screening Program Dayna R Cenin BSc(Hons), GradDipEd, MPH Bowel Cancer Education Coordinator 1 D James B St John MD, FRACP, FRCP(UK) Honorary Senior
More informationColorectal cancer screening guidelines clearly recommend. Comparing Risks and Benefits of Colorectal Cancer Screening in Elderly Patients
GASTROENTEROLOGY 2005;129:1163 1170 Comparing Risks and Benefits of Colorectal Cancer Screening in Elderly Patients CYNTHIA W. KO* and AMNON SONNENBERG *Department of Medicine, University of Washington,
More informationAppendix 1: Description of the 25 studies excluded from the meta-analysis of Sensitivity
Supplementary Data Appendix 1: Description of the 25 studies excluded from the meta-analysis of Sensitivity and Specificity. Below we list each study excluded from our meta-analysis of the sensitivity
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationMerit-based Incentive Payment system (MIPS) 2018 Qualified Clinical Data Registry (QCDR) Measure Specifications
Merit-based Incentive Payment system (MIPS) 2018 Qualified Clinical Data Registry (QCDR) Measure Specifications This document contains a listing of the clinical quality measures which the New Hampshire
More informationabstract n engl j med 371;9 nejm.org August 28,
The new england journal of medicine established in 1812 August 28, 2014 vol. 371 no. 9 Long-Term Colorectal-Cancer Mortality after Adenoma Removal Magnus Løberg, M.D., Mette Kalager, M.D., Ph.D., Øyvind
More informationCost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies
Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies M. Elske van den Akker-van Marle, Marjolein van Ballegooijen, Gerrit J. van Oortmarssen, Rob Boer, J. Dik F. Habbema Background:
More information50 세미만인구에서용종절제술로제거된대장선종의특성 : 대한장연구학회전향적다기관공동연구
50 세미만인구에서용종절제술로제거된대장선종의특성 : 대한장연구학회전향적다기관공동연구 The Characteristics of Colorectal Adenoma with Colonoscopic Polypectomy in Population under 50 Years Old: The KASID Prospective Multicenter Study Hyun Joo
More informationWhen is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool
When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs
More informationIncidence and Recurrence Rates of Colorectal Adenomas: A Prospective Study
GASTROENTEROLOGY 1995;108:402-408 Incidence and Recurrence Rates of Colorectal : A Prospective Study ALFRED I. NEUGUT,*'* JUDITH S. JACOBSON,* HABIBUL AHSAN,* JASON SANTOS,* GAlL C. GARBOWSKI,* KENNETH
More informationStaging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans
Original Article Staging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans Gurjiwan Sing Virk 1, Mikram Jafri 2, Syed Mehdi 3, Christopher Ashley 4 1 Department
More informationMeasuring performance and quality indicators of CRC screening
Measuring performance and quality indicators of CRC screening Ondřej MÁJEK Institute of Biostatistics and Analyses, Masaryk University Institute of Biostatistics and Analyses, Masaryk University, Brno
More informationRomanian Journal of Morphology and Embryology 2006, 47(3):
Romanian Journal of Morphology and Embryology 26, 7(3):239 23 ORIGINAL PAPER Predictive parameters for advanced neoplastic adenomas and colorectal cancer in patients with colonic polyps a study in a tertiary
More informationThe Prevalence Rate and Anatomic Location of Colorectal Adenoma and Cancer Detected by Colonoscopy in Average-Risk Individuals Aged Years
American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00430.x Published by Blackwell Publishing The Prevalence Rate and Anatomic Location
More informationColorectal cancer screening
26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant
More informationCLINICAL MANAGEMENT Loren Laine, M.D. Clinical Management Editor University of Southern California Los Angeles, California
GASTROENTEROLOGY 2004;126:1167 1174 CLINICAL MANAGEMENT Loren Laine, M.D. Clinical Management Editor University of Southern California Los Angeles, California Rectal Bleeding and Diminutive Colon Polyps
More informationResearch Article Development of Polyps and Cancer in Patients with a Negative Colonoscopy: A Follow-Up Study of More Than 20 Years
ISRN Gastroenterology, Article ID 261302, 4 pages http://dx.doi.org/10.1155/2014/261302 Research Article Development of Polyps and Cancer in Patients with a Negative Colonoscopy: A Follow-Up Study of More
More informationDeakin Research Online
Deakin Research Online This is the authors final peer reviewed (post print) version of the item published as: Tran, Ben, Keating, Catherine L., Ananda, Sumitra S., Kosmider, Suzanne, Jones, Ian, Croxford,
More informationTHE EFFECT OF FECAL OCCULT-BLOOD SCREENING ON THE INCIDENCE OF COLORECTAL CANCER
THE EFFECT OF FECAL OCCULT-BLOOD SCREENING ON THE INCIDENCE OF COLORECTAL CANCER JACK S. MANDEL, PH.D., M.P.H., TIMOTHY R. CHURCH, PH.D., JOHN H. BOND, M.D., FRED EDERER, M.A., MINDY S. GEISSER, M.S.,
More informationT he lifetime risk of developing colorectal cancer is 5%, with. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer CANCER
228 CANCER Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer G Lindgren, A Liljegren, E Jaramillo, C Rubio, A Lindblom... See end of article for authors affiliations... Correspondence
More informationScreening for colorectal cancer
Postgrad Med J (1994) 70, 469-474 A) The Fellowship of Postgraduate Medicine, 1994 Review Article Screening for colorectal cancer D.H. Bennett and J.D. Hardcastle Department ofsurgery, E Floor, West Block,
More informationSummary. Cezary ŁozińskiABDF, Witold KyclerABCDEF. Rep Pract Oncol Radiother, 2007; 12(4):
Rep Pract Oncol Radiother, 2007; 12(4): 201-206 Original Paper Received: 2006.12.19 Accepted: 2007.04.02 Published: 2007.08.31 Authors Contribution: A Study Design B Data Collection C Statistical Analysis
More informationThe Natural History of Right-Sided Lesions
The Natural History of Right-Sided Lesions Jasper L.A. Vleugels Dept of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands. None Disclosures Agenda Is there evidence that
More informationFeasible economic strategies to improve screening compliance for colorectal cancer in Korea
PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(11):1587-1593 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com ELSEVIER 2005 The WJG Press and Elsevier Inc.
More informationColorectal cancer is the third leading
doi: 10.1377/hlthaff.2008.0898 HEALTH AFFAIRS 29, NO. 9 (2010): 1734 1740 2010 Project HOPE The People-to-People Health Foundation, Inc. By Sujha Subramanian, Georgiy Bobashev, and Robert J. Morris When
More informationCOLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.
The West London Medical Journal 2009 Vol No 1 pp 23-31 COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. Competing interests: None declared ABSTRACT Sarah
More informationCost-effectiveness of colonoscopy in screening for colorectal cancer Sonnenberg A, Delco F, Inadomi J M
Cost-effectiveness of colonoscopy in screening for colorectal cancer Sonnenberg A, Delco F, Inadomi J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationDECISION MODEL AND COST-EFFECTIVENESS ANALYSIS OF COLORECTAL CANCER
DECISION MODEL AND COST-EFFECTIVENESS ANALYSIS OF COLORECTAL CANCER SCREENING AND SURVEILLANCE GUIDELINES FOR AVERAGE-RISK ADULTS Rezaul K. Khandker, Jane D. Dulski, Jeffrey B. Kilpatrick, Randall P. Ellis,
More informationReferences Cleveland Clinic. Diseases and Conditions. Colorectal Cancer Overview. 29 October 2013
Colo-Alert Only available DNA based rapid test for early colorectal cancer detection. The earlier colon cancer is found, the easier it is to treat. This is why regular screening is worthwhile it has the
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationColonoscopy with polypectomy significantly reduces colorectal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:562 567 Utilization and Yield of Surveillance Colonoscopy in the Continued Follow-Up Study of the Polyp Prevention Trial ADEYINKA O. LAIYEMO,*, PAUL F. PINSKY,
More informationColonoscopy screening for colorectal cancer: the outcomes of two recruitment methods
Colonoscopy screening for colorectal cancer: the outcomes of two recruitment methods Mike Corbett, Sharon L Chambers, Bruce Shadbolt, Lybus C Hillman and Doug Taupin One in 20 Australians will develop
More informationTHE risk of colorectal cancer in the families of patients
82 THE NEW ENGLAND JOURNAL OF MEDICINE Jan. 11, 1996 RISK OF COLORECTAL CANCER IN THE FAMILIES OF PATIENTS WITH ADENOMATOUS POLYPS SIDNEY J. WINAWER, M.D., ANN G. ZAUBER, PH.D., HANS GERDES, M.D., MICHAEL
More informationThe relative economics of screening for colorectal cancer, breast cancer and cervical cancer
Critical Reviews in Oncology/Hematology 32 (1999) 133 144 www.elsevier.com/locate/critrevonc The relative economics of screening for colorectal cancer, breast cancer and cervical cancer Dorte Gyrd-Hansen*
More informationLatest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population
Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics
More informationCA Cancer J Clin 2006;56:
Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the US Multi- Society Task Force on Colorectal Cancer and the American Cancer Society *, Sidney J. Winawer, MD; Ann G. Zauber,
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationColorectal cancer (CRC), the second leading cause of
GASTROENTEROLOGY 2007;132:96 102 Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis BRIAN BRESSLER,* LAWRENCE F. PASZAT,, ZHONGLIANG CHEN, DEANNA
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 A UGUST 23, 2001 NUMBER 8 ONE-TIME SCREENING FOR COLORECTAL CANCER WITH COMBINED FECAL OCCULT-BLOOD TESTING
More informationBackground and Rationale for Gipson bill AB The imperative for colonoscopy after a positive FOBT (Fecal Occult Blood Test)
Background and Rationale for Gipson bill AB 1763 The imperative for colonoscopy after a positive FOBT (Fecal Occult Blood Test) The Affordable Care Act (ACA) requires all private insurers (except grandfathered
More informationColorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005
Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005 David Lieberman MD Chief, Division of Gastroenterology Oregon Health and Science University Portland VAMC Portland, Oregon
More informationNational Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT
National Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT 00102011 Ann Zauber Sidney Winawer, Michael O Brien, John Allen, Andrew Feld, Glenn Mills, Robin Mendelsohn,
More informationTechnical Considerations: the past, present and future of simulation modeling of colorectal cancer
Technical Considerations: the past, present and future of simulation modeling of colorectal cancer Siddhartha Nambiar, Rachel Townsley, Maria Mayorga North Carolina State University Kristen Hassmiller
More informationImpact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationDebate: General surveillance/screening for colon cancer in a resource constrained environment is imperative
Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Dr. Meryl Oyomno Department of surgery, University of Pretoria INTRODUCTION Screening is the
More informationThe Influence of Snare Size on the Utility and Safety of Cold Snare Polypectomy for the Removal of Colonic Polyps in Japanese Patients
Elmer ress Original Article J Clin Med Res. 2016;8(9):662-666 The Influence of Snare Size on the Utility and Safety of Cold Snare Polypectomy for the Removal of Colonic Polyps in Japanese Patients Hisatsugu
More informationQuality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right?
Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Hartery K 1, Sukha A 1, Thomas-Gibson S 1, Thomas H 1,2, Latchford A 1,2. 1 Wolfson Endoscopy Unit, St.
More informationSCREENING FOR COLON AND RECTAL CANCER
Review Article SCREENING FOR COLON AND RECTAL CANCER Jack S. Mandel, PhD, MPH School of Public Health, University of Minnesota Introduction Approximately 138,200 new cases and 55,300 deaths occured in
More informationUpdates in Colorectal Cancer Screening & Prevention
Updates in Colorectal Cancer Screening & Prevention Swati G. Patel, MD MS Assistant Professor of Medicine Division of Gastroenterology & Hepatology Gastrointestinal Cancer Risk and Prevention Clinic University
More information2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)
Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,
More information